Comparing the current results to its competitors, Tonix Pharmaceuticals Holding reported Revenue increase in the 2 quarter 2026 by 577.88 % year on year. The sales growth was above Tonix Pharmaceuticals Holding 's competitors' average revenue growth of 16.9 %, achieved in the same quarter.
Tonix Pharmaceuticals Holding Corp , slower than the average decrease reported by the company's competitors of -91.97 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -91.97 %
Tonix Pharmaceuticals Holding 's Comment on Competition and Industry Peers
The company operates in a highly competitive sector marked by rapid global technological advancements. Its competitors include major pharmaceutical and biotechnology firms, specialty pharmaceutical and generic drug manufacturers, academic institutions, government agencies, and research organizations. Key competitive factors include efficacy, safety, tolerability, reliability, pricing, and reimbursement levels. Many competitors possess significantly greater financial, technical, and human resources, along with extensive experience in drug development, regulatory approvals, and commercialization, which may enhance their ability to secure FDA approvals and achieve market acceptance. Competitors' drugs may be more effective or better marketed, potentially rendering the company's product candidates obsolete or non-competitive. The company expects increased competition from new drugs, advanced technologies, and novel treatment approaches that could reduce the relevance of its products.
Due to outstanding performance in Overall company, revenue grew by 577.88 % Tonix Pharmaceuticals Holding Corp improved its market share, to approximately 0.06 %.
March 4, 2025
In a noteworthy presentation at the 7th International Congress on Controversies in Fibromyalgia, Tonix Pharmaceuticals showcased groundbreaking data regarding its innovative therapeutic agent, TNX-102 SL. This sublingual formulation of cyclobenzaprine, designed for effective transmucosal delivery, holds the potential for durable therapeutic activity in the challenging landscape of fibromyalgia treatment.Fibromyalgia affects millions worldwide, presenting a myriad of persistent symptoms, including widespread pain, fatigue, and cognitive disturbances. Patients often grapple with the debilitating nature of the condition, leading to disrupted daily lives and substantial healthcare burdens. Despite this, treatmen...
December 17, 2024
The pharmaceutical landscape for fibromyalgia (FM) is evolving, as companies pursue innovative treatments to enhance the quality of life for patients. While fibromyalgia has been historically challenging to treat, recent advancements signal potential improvements in patient outcomes. Tonix Pharmaceuticals is at the forefront of these efforts with their novel drug candidate, TNX-102 SL (sublingual cyclobenzaprine HCl). This article explores the recent developments surrounding TNX-102 SL, including FDA acceptance of its New Drug Application (NDA), ongoing research in fibromyalgia-type Long COVID, and the latest clinical data presentations at international scientific forums. FDA Acceptance of TNX-102 SL for Fib...
November 13, 2024
In response to the escalating public health threats posed by the Mpox virus, Tonix Pharmaceuticals has made significant strides in vaccine development. Recent findings, published in the peer-reviewed journal mSphere, underscore the potential of TNX-801, a single-dose live attenuated virus vaccine candidate for Mpox and smallpox, particularly in immune-compromised animal models. The urgency of addressing Mpox outbreaks has been amplified by the World Health Organization s (WHO) declaration of these incidents as public health emergencies of international concern. This article discusses the implications of these developments, as well as Tonix s broader commitment to addressing health issues related to gastropa...
August 29, 2024
: Tonix Pharmaceuticals has showcased significant advancements in their investigational product TNX-102 SL at the 2024 Military Health System Research Symposium (MHSRS). Presenting data from two posters focusing on the potential of TNX-102 SL in the reduction of acute stress reactions (ASR) and the prevention of post-traumatic stress disorder (PTSD), the company also highlighted its applications in wound healing. With plans for a Phase 2 trial set to commence in the third quarter of 2024, these efforts signify a notable increase in research directed towards intervention strategies for military personnel and trauma-affected populations. Acute stress reactions are common responses to extreme stressors, ofte...
August 26, 2024
In a significant step forward in public health, Tonix Pharmaceuticals and Bilthoven Biologicals have announced a collaborative effort aimed at accelerating the development of Tonix’s Mpox vaccine, TNX-801. This partnership comes at a crucial time as the World Health Organization (WHO) recently declared the resurgence of mpox a disease previously known as monkeypox a public health emergency of international concern (PHEIC) for the second time in two years. The renewed alert by the WHO underlines the urgency of addressing mpox and the need for effective vaccination solutions. The Urgency of ActionThe WHO s classification of mpox as a PHEIC signals that this viral infection poses a significant risk to global ...
August 16, 2024
In a crucial development in the fight against mpox, Tonix Pharmaceuticals Holding Corp has issued an update regarding its promising vaccine candidate, TNX-801, which is a single-dose live attenuated virus vaccine designed to combat the disease. This update comes on the heels of the World Health Organization’s (WHO) declaration of a public health emergency of international concern (PHEIC) in response to a rising number of mpox cases across multiple African nations.Mpox, previously referred to as monkeypox, has seen a significant resurgence recently, prompting the WHO’s urgent call to action. As the global health community intensifies its focus on mitigating the outbreak, Tonix Pharmaceuticals is pressing ...
June 12, 2024
Tonix Pharmaceuticals Executes $4.0 Million Public OfferingCHATHAM, New Jersey, June 12, 2024 Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), an established leader in the biopharmaceutical industry, today announced an important milestone: the company has entered into a placement agency agreement facilitating the public offering of 3,753,558 shares of its common stock. Investors may also choose pre-funded warrants instead of common shares, with a negligible price difference between the two at $1.065 per share or $1.064 per warrant.The total capital to be raised from this public offering is approximately $4.0 million. The financial injection will be pivotal for Tonix Pharmaceuticals as it continues its ...
May 21, 2024
Fibromyalgia, a complex chronic pain disorder characterized by widespread musculoskeletal pain and associated symptoms, continues to pose significant challenges for both patients and healthcare providers. The need for effective and safe treatment options for fibromyalgia management has spurred pharmaceutical companies to develop innovative approaches. Tonix Pharmaceuticals has recently announced key findings from the initial phase of their market opportunity analysis for Tonmya, a potential new first-line, centrally acting non-opioid analgesic, for the management of fibromyalgia. This article aims to explore the significance of Tonmya s statistically significant results from two Phase 3 trials and its potent...
March 21, 2024
The American Chemistry Society (ACS) Spring 2024 Meeting witnessed a groundbreaking announcement by Tonix Pharmaceuticals, unraveling the discovery of novel next-generation oxytocin analogues. This discovery holds immense potential for advancing various therapeutic possibilities in multiple medical domains. Furthermore, Tonix Pharmaceuticals is currently conducting four Phase 2 investigator-initiated studies evaluating the efficacy of TNX-1900, an intranasal potentiated oxytocin, in the management of pediatric obesity, binge eating disorder, bone health in autism, and social anxiety disorder. This article delves into the significance of this exciting development and its implications for the pharmaceutical in...
February 28, 2024
Tonix Pharmaceuticals Progresses in the Development of TNX-1500 and Its Potential Impact on Kidney Transplant RejectionWith the increasing demand for organ transplantation worldwide, finding effective ways to prevent graft rejection is crucial. Tonix Pharmaceuticals recently completed the clinical stage of its Phase 1 trial for TNX-1500, a promising Fc-modified humanized anti-CD40L monoclonal antibody (mAb). This significant milestone not only marks the completion of a successful safety assessment but also paves the way for future research on the prevention of kidney transplant rejection. This article aims to provide an extensive analysis of the implications of TNX-1500 and the potential impact it may have i...
Rain Therapeutics Inc is a biopharmaceutical company that focuses on discovering and developing precision oncology therapies. Their business model revolves around identifying genetic alterations and biomarkers in cancer patients, and then developing targeted therapies to address these specific alterations. By tailoring treatments to individual patients, they aim to improve outcomes and provide more effective and personalized cancer care.
Rapt Therapeutics Inc operates based on a business model that focuses on developing and commercializing transformative oral small molecules, known as immunomodulators. Their compounds target specific immune cell subsets within the body to provide potential therapeutic benefits in various diseases. By leveraging their expertise in immunology and small molecule drug design, Rapt strives to deliver innovative treatment options to patients in need.
Regeneron Pharmaceuticals Inc operates a business model centered on the discovery and commercialization of cutting-edge biopharmaceuticals, particularly in the fields of ophthalmology, oncology, immunology, and rare diseases. They leverage their strong research and development capabilities, including their proprietary technologies, to create innovative therapies that address unmet medical needs. Additionally, Regeneron forms strategic collaborations and partnerships to enhance their development pipeline and expand market access for their products.
Repare Therapeutics Inc is a biotechnology company that specializes in the development of precision oncology drugs. Their business model focuses on leveraging synthetic lethality, a targeted therapy approach, to identify and develop small molecule drugs for the treatment of various forms of cancer. By discovering and advancing novel therapeutics, Repare Therapeutics aims to improve patient outcomes and address unmet medical needs in oncology.
Sources:
Tonix Pharmaceuticals Holding Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Tonix Pharmaceuticals Holding Corp versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
